Nonrespiratory complications of nusinersen‐treated spinal muscular atrophy type 1 patients-Reference-Cited by-同舟云学术

Nonrespiratory complications of nusinersen‐treated spinal muscular atrophy type 1 patients

Published:2022-01-03 Issue: Volume: Page:
ISSN:8755-6863
Container-title:Pediatric Pulmonology
language:en
Short-container-title:Pediatric Pulmonology

Author:

Lavie Moran¹^ORCID,Rochman Mika¹,Sagi Liora²,Yerushalmy Feler Anat³,Ovadia Dror⁴,Cahal Michal¹^ORCID,Be'er Moria¹^ORCID,Sadot Efraim¹⁵,Fattal‐Valevski Aviva²,Amirav Israel¹^ORCID

Affiliation:

1. Pediatric Pulmonology Unit, Tel‐Aviv Sourasky Medical Center, Dana‐Dwek Children's Hospital, Affiliated to the Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

2. Pediatric Neurology Institute, Tel‐Aviv Sourasky Medical Center, Dana‐Dwek Children's Hospital, Affiliated to the Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

3. Pediatric Gastroenterology Unit, Tel‐Aviv Sourasky Medical Center, Dana‐Dwek Children's Hospital, Affiliated to the Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

4. Pediatric Orthopedic Department, Tel‐Aviv Sourasky Medical Center, Dana‐Dwek Children's Hospital, Affiliated to the Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

5. Pediatric Intensive Care Unit, Tel‐Aviv Sourasky Medical Center, Dana‐Dwek Children's Hospital, Affiliated to the Sackler Faculty of Medicine Tel Aviv University Tel Aviv Israel

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ppul.25795

Reference35 articles.

1. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care

2. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics

3. Observational study of spinal muscular atrophy type I and implications for clinical trials

4. Special Considerations in the Respiratory Management of Spinal Muscular Atrophy

5. Respiratory Complications of Pediatric Neuromuscular Diseases

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nutrition outcomes of disease modifying therapies in spinal muscular atrophy: A systematic review;Muscle & Nerve;2024-08-11

2. An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies;European Journal of Paediatric Neurology;2024-07

3. Evaluation of the therapeutic efficacy and tolerability of current drug treatments on the clinical outcomes of paediatric spinal muscular atrophy type 1: A systematic review;Paediatric Respiratory Reviews;2023-12

4. Decision-making and challenges within the evolving treatment algorithm in spinal muscular atrophy: a clinical perspective;Expert Review of Neurotherapeutics;2023-06